FDA OKs Hep C Indication for Promacta
WASHINGTON (MedPage Today) — The FDA has approved eltrombopag (Promacta) for the additional indication of treating low blood platelet counts in patients with chronic hepatitis C.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com